Quick Facts: Uses of Depostat (Daprodustat)

• Therapeutic Domain: Anemia associated with long-term kidney dysfunction.
• Patient Population: Adults receiving maintenance dialysis.
• Key Action: Supports the body in generating red blood cells.

What Depostat Treats: Main Uses and Benefits

Depostat (daprodustat) is an approved prescription medication used for the management of anemia in a specific group of adult patients. Anemia, a condition characterized by a reduced number of red blood cells, is a common complication that may occur in individuals with chronic kidney disease (CKD).

This medicine is designated for use in adults who have been consistently receiving dialysis for a duration of at least four months. It is utilized to help increase and sustain the appropriate level of hemoglobin in the blood, which is the protein responsible for transporting oxygen.

By helping to raise hemoglobin levels, Depostat supports the body’s oxygen-carrying capacity. The therapeutic purpose of this treatment is to address the underlying deficiency in red blood cell production that is frequently observed in dialysis-dependent CKD.

Depostat is not intended as a substitute for blood transfusions when immediate correction of anemia is required, nor is it currently approved for the treatment of anemia in individuals with CKD who are not on dialysis.

Eligibility Map: Who Can and Cannot Use Depostat (Daprodustat)

The eligibility for Depostat (Daprodustat) is strictly defined by regulatory authorities for use only in adults with anemia due to Chronic Kidney Disease (CKD) who have been receiving maintenance dialysis for a minimum of four months.

The official regulatory documents classify several patient groups as non-eligible:

Safety and effectiveness have not been established in pediatric patients (under 18 years). Furthermore, initiation is avoided in patients who have experienced a myocardial infarction, stroke, or TIA within the previous three months due to an increased risk of thrombotic events. The regulatory label states the medication may cause fetal harm, and breastfeeding is not recommended during treatment and for one week following the final dose.

Interaction Map: Interactions with other medicines and products — official regulatory information for Daprodustat

Resulting Interaction Structure

Official interaction statements:

• Co-administration with strong CYP2C8 inhibitors (e.g., Gemfibrozil) is contraindicated due to a marked increase in systemic exposure.
• Moderate CYP2C8 inhibitors (e.g., Clopidogrel) increase exposure, requiring a dose adjustment as defined in regulatory labeling.
• CYP2C8 inducers (e.g., Rifampin) decrease daprodustat exposure, which may reduce the therapeutic effect.
• Use with substances that increase the risk of GI erosion (e.g., NSAIDs, alcohol/tobacco) reinforces the potential for serious GI adverse events.

Connection to the overall interaction profile (2–4 sentences): The official regulatory profile for daprodustat is largely determined by the CYP2C8 enzyme metabolism. This results in the classification of strong inhibitors as a prohibited combination and necessitates specific dosage modifications for co-administered inhibitors and inducers. Furthermore, the label confirms no mandatory timing separation is required when taking the drug with food, iron supplements, or phosphate binders.

Depostat, a synthetic progestogen, exerts its action by binding to and activating nuclear progesterone receptors ( nPR-A and nPR-B) within cellular nuclei. The activated ligand-receptor complex interacts with progesterone response elements (PREs) on the DNA, thereby modulating the transcription and subsequent expression of specific genes. This molecular event initiates an antigonadotropic cascade, primarily through the suppression of luteinizing hormone (LH) release from the pituitary gland. This suppression, in turn, results in a systemic reduction of gonadal sex hormone production, chiefly testosterone and estradiol. Additionally, Depostat exerts localized activity by inhibiting the uptake of circulating testosterone into target cells. It also functions as an inhibitor of the 5alpha-reductase enzyme, which reduces the metabolic conversion of testosterone into the more potent dihydrotestosterone (DHT). The combined effect of these interactions is a multi-faceted physiological modulation leading to a diminished androgenic stimulus in sensitive tissues.

How to use Depostat (Daprodustat): Official Administration Guidelines

Depostat is an oral medication administered to adults receiving maintenance dialysis. The use of this drug is highly standardized, with specific rules governing the initial dose, timing, and ongoing adjustments set by regulatory authorities.

Dosing and Administration Schedule

Labeled Dosing Regimens

The starting dose is highly individualized based on the patient’s existing treatment status. For patients who have not previously taken an erythropoiesis-stimulating agent (ESA), the starting dose ranges from 1 mg to 4 mg once daily, determined by the pre-treatment hemoglobin level. Patients switching from an ESA receive a converted starting dose, ranging from 4 mg to 12 mg once daily. The maximum recommended daily dose is 24 mg.

Procedural Constraints

The protocol dictates that hemoglobin levels must be monitored on a fixed schedule. If a dose is missed, it should be taken as soon as possible, unless it is the same day as the next scheduled dose, in which case the missed dose should be skipped; double doses are prohibited. Furthermore, treatment must be interrupted if the hemoglobin level exceeds 12 g/dL and resumed at a lower dose when the level returns to the target range. Specific dose reductions are required for patients with moderate hepatic impairment or those taking certain concomitant CYP2C8 inhibitors.

Depostat: Recent Clinical Evidence

Evidence for Use in Anemia Associated with Kidney Disease in Dialysis-Dependent Adults

The research base that informs the regulatory review of Depostat (daprodustat) consists primarily of large, multinational Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving adult patients with chronic kidney disease (CKD) who were already receiving either hemodialysis or peritoneal dialysis. Researchers examined outcomes related to a systemic or functional imbalance, specifically monitoring hemoglobin levels to track whether they remained within a set range. The trials were structured with an active comparator, meaning Depostat was studied against the established standard of care treatments, known as Erythropoiesis-Stimulating Agents (ESAs).

Studies report how hemoglobin levels evolved in the observed populations. The primary RCTs described patterns observed in participants receiving Depostat and those receiving ESA treatment for the key endpoints. The research also closely monitored participants for outcomes such as the occurrence of Major Adverse Cardiovascular Events (MACE). Reports suggest patterns observed in the studies related to these safety endpoints were within the prespecified limits when compared to the ESA group. Findings describe patterns observed in these studies, which were conducted over follow-up periods that extended for several years.

Comparing Depostat to Standard Treatments

The largest clinical trials involved a direct comparison to the existing standard of care for anemia in dialysis patients. The research was structured to compare the outcomes observed in the Depostat group against the outcomes observed in the established standard treatments (ESAs). These studies explored whether key outcomes, such as maintaining stable hemoglobin, were achieved under similar conditions as the active control. The findings contribute to the broader evidence landscape by examining differences in measured outcomes between the two treatment groups.

What Research Gaps and Uncertainties Remain

While the clinical development program provided high-level evidence for use in dialysis-dependent adults, certain aspects remain uncertain. Due to some findings observed in trials involving patients who were not on dialysis, regulatory bodies have restricted the approved use to the dialysis population, noting that the risk-benefit balance in the non-dialysis group was not characterized with the same certainty. Furthermore, research provides limited insight into certain outcomes. For example, evidence related to patient-reported outcomes describing perceived discomfort, fatigue, or overall quality of life is limited, as these were not the primary endpoints of the definitive trials. The long-term effects of the drug class are not fully characterized, and research is ongoing.

Key Studies & References Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis (ASCEND-D Trial)

Common questions about Depostat (FAQ)

Q: What is the main purpose or reason doctors prescribe Depostat?

A: Official product information states that Depostat is prescribed for the treatment of anemia in adult patients with Chronic Kidney Disease (CKD). The drug is intended only for those who have been receiving maintenance dialysis for a minimum of four months.

Q: What conditions or symptoms is Depostat officially approved to treat?

A: The official regulatory approval for Depostat is specific. It is approved only for the treatment of anemia that is due to chronic kidney disease in adult patients who are currently on maintenance dialysis.

Q: Is Depostat a first-line medication, or is it used after other treatments fail?

A: Official information indicates that injectable Erythropoiesis-Stimulating Agents (ESAs) have historically been the standard of care for this condition. Depostat may be considered in various positions in the treatment strategy, including for patients who may have shown a suboptimal response to those existing treatments.

Q: How does the action of Depostat differ from other similar medications?

A: Depostat works by stabilizing the HIF (hypoxia-inducible factor) protein, which mimics the body’s natural response to lower oxygen levels. This process promotes the body's own production of erythropoietin (a hormone that stimulates red blood cell production). This mechanism is different from standard treatments (ESAs), which are synthetic versions of the erythropoietin hormone itself.

Q: Is Depostat a medication designed for short-term or long-term use?

A: Because it is used to manage the chronic, ongoing condition of anemia associated with CKD, Depostat is generally intended for long-term use. Treatment continues as long as the patient's condition responds to the medication and they meet the criteria for maintenance therapy.

Q: What are the observable signs that Depostat is working effectively?

A: The clinical effectiveness of Depostat is measured by the healthcare team tracking and maintaining the patient's hemoglobin levels within a specific target range. The official drug label notes that the medication is not shown to improve subjective patient experiences such as fatigue or overall quality of life.

Q: What is the typical duration of treatment with Depostat?

A: Treatment with Depostat is typically ongoing and continued as long as the medication successfully helps the patient achieve and sustain the target hemoglobin levels. The duration is therefore tied to the continued need for maintenance therapy for chronic kidney disease anemia.

Q: Does taking Depostat cause changes in weight (gain or loss)?

A: While weight change is not listed as a common side effect, the official label does warn that sudden weight gain can be a symptom of a serious risk, specifically heart failure. A patient experiencing this type of symptom is generally advised to seek medical attention.

Q: Does Depostat have a known risk of causing changes in mood or anxiety?

A: Regulatory safety reports classify anxiety as a rare side effect of the medication. Additionally, general mood or mental changes have been listed among side effects where the incidence rate is unknown.

Q: Can Depostat cause issues with sleep, such as insomnia or drowsiness?

A: In some regulatory reports, drowsiness is listed among the side effects of unknown incidence. Additionally, the drug is associated with a risk of high blood pressure, and severe symptoms of dangerously high blood pressure may include confusion, which could affect rest.

Q: Are there ways described in official sources to manage or lessen common side effects?

A: Official documents state that because worsening hypertension (high blood pressure) is a known risk, the patient’s blood pressure is monitored regularly. Healthcare providers will then adjust any existing anti-hypertensive therapy as needed to help manage this side effect.

Q: What common over-the-counter medications should be checked for interactions with Depostat?

A: Regulatory information indicates that many common over-the-counter medications, particularly Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen or naproxen, are identified as potential interacting substances. Co-administration of these can increase the risk of serious gastrointestinal adverse events.

Q: Is there a potential interaction between Depostat and blood pressure medications?

A: Yes, official warnings state that worsening hypertension is a risk with Depostat. The label states that monitoring blood pressure and adjusting anti-hypertensive therapy may be needed, confirming a necessary management relationship between Depostat and blood pressure medications.

Q: Does Depostat need to be taken at the exact same time every day for maximum effect?

A: The medication is directed to be taken one time a day. For consistent effect, official product information indicates that the medication is generally administered at around the same time every day.

Q: Why might a healthcare provider recommend discontinuing Depostat treatment?

A: Official warnings state that treatment may be discontinued or interrupted if the patient develops uncontrolled hypertension, has an active malignancy (cancer), or if their hemoglobin levels rise above 12 g/dL. This decision is based on clinical necessity and determined by the prescribing healthcare provider.

Q: Can older adults or seniors safely use Depostat?

A: Clinical trial data examined the effectiveness of Depostat in different age groups. Official findings indicated the drug was similarly effective in patients younger than 65 years, those between 65 and 75 years, and those who were older than 75 years.

Q: Has Depostat been studied across various ethnic groups or specific patient populations?

A: Clinical trials for Depostat included participants from various ethnic backgrounds. Official trial snapshots confirmed that the drug was found to work similarly in both White and Black or African American patients who participated in the studies.

Q: Is Depostat associated with any effects on vision or eye health?

A: Official side effect information lists blurred vision as a reported side effect. Additionally, changes in vision may be a symptom of dangerously high blood pressure, which is a serious risk associated with the drug.

Q: Do any official documents describe potential long-term risks of Depostat that patients should know about?

A: Yes, the label carries a Boxed Warning that highlights serious long-term risks. These include an increased risk of death, myocardial infarction (heart attack), stroke, and venous thromboembolism (blood clots).

Official Storage and Disposal Requirements

Storage of Depostat must strictly follow the conditions specified on the regulatory label to maintain quality and effectiveness. The product must be stored within the mandatory temperature range (e.g., Controlled Room Temperature or Refrigerated) and kept protected from environmental factors, including excessive heat, freezing, light, and moisture.

It is required to keep the medicine in its original container to preserve stability and must always be stored out of the reach of children. If the product is reconstituted or opened, specific in-use stability periods and new storage requirements may apply as defined in the official prescribing information.

Disposal must adhere to local pharmaceutical take-back programs or authorized collection sites. Do not dispose of unused or expired Depostat in household trash or pour it down a sink or toilet, as mandated by regulatory guidelines.